06th week of 2010 patent applcation highlights part 46 |
Patent application number | Title | Published |
20100035911 | DRUG COMBINATIONS TO TREAT HYPERPROLIFERATIVE DISORDERS - A method of treating a hyperproliferative disorder, including a cancer, in a subject in need of such treatment, comprising administering to said subject a pharmaceutical combination containing a treatment effective amount of: (a) a vitamin A derivative (i.e., a retinoid), or a pharmaceutically acceptable salt thereof, and an inhibitor of microtubule structure or function; or (b) a combination containing fenretinide (i.e., N-(4-hydrophenyl) retinamide, 4-HPR) and ABT-751 (i.e., N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide). Vitamin A derivatives that may be useful for this invention according to (a) include, but are not limited to, all-trans-retinoic acid, 13-cis-retinoic acid, and fenretinide. Microtubule inhibitors that may be useful for this invention according to (a) include, but are not limited to, inhibitors of the Vinca binding domain (e.g., vincristine, vinblastine, vinorelbine, and cryptophycin 52), inhibitors of the Taxane domain (e.g., paclitaxel, docetaxel, and epothilones), and inhibitors of the colchicine site (e.g., colchicine, ABT-751, CI-980, and combretastatin). A preferred retinoid according to (a) is fenretinide. A preferred microtubule inhibitor according to (b) is ABT-751. | 2010-02-11 |
20100035912 | Small Molecule Inhibitors of Retroviral Assembly and Maturation - Chemical compounds that disrupt retroviral assembly and maturation are presented herein. More particularly, this disclosure provides small molecule compounds that disrupt the formation and maturation of virus particles and methods of using such small molecules to treat HIV-1 infection. | 2010-02-11 |
20100035913 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors - The compounds of a certain formula (1), | 2010-02-11 |
20100035914 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE - The present invention relates to novel compounds of formula (I)′, and pharmaceutically acceptable salts, prodrugs or solvates thereof: | 2010-02-11 |
20100035915 | INDOLIZINE DERIVATIVES AND THE USE THEREOF AS ANTIDIABETICS - Novel compounds of the formula (I), in which X, Y, R, R | 2010-02-11 |
20100035916 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY - The invention relates to compounds of the general formula (I): | 2010-02-11 |
20100035917 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS - The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to Formula (1) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular 1KK2 activity. | 2010-02-11 |
20100035918 | Imidazolone Compounds and Methods of Making and Using the Same - In one aspect, the invention features a compound of the general Formula (I). Compounds of Formula (I) possess high affinity for Alk 5 and/or AIk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. | 2010-02-11 |
20100035919 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES - Disclosed herein are compounds of formula (I) or pharmaceutical acceptable salts thereof, | 2010-02-11 |
20100035920 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE - The present invention is directed to substituted pyrazolo[1,5-a]pyridines and related methods for their synthesis and use. | 2010-02-11 |
20100035922 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF - Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases. | 2010-02-11 |
20100035923 | VR1 VANILLOID RECEPTOR ANTAGONISTS WITH A IONONIC SUBSTRUCTURE - The invention provides compounds of formula (I), wherein Y, R, n and X are as defined in the description, a process for their preparation and pharmaceutical compositions containing them. The compounds of formula (I) inhibit the Transient Receptor Potential Vanilloid 1 (TRPV1), which plays a pivotal role in the development of post-inflammatory analgesia, therefore they can be used as analgesic and anti-inflammatory drugs. | 2010-02-11 |
20100035924 | NOVEL 4-AMINO-PYRIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel 4-amino-pyridine derivative useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2010-02-11 |
20100035925 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AN DMETHODS FOR INHIBITING HIV INFECTIVITY - Compounds that possess anti-infective activity are described. Methods of using these compounds for the treatment or prevention of infectious diseases such as acquired immunodeficiency syndrome (AIDS) are also described. The compounds inhibit HIV infectivity and do not exhibit significant cytotoxicity in HIV producing cells. | 2010-02-11 |
20100035926 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS - The present invention provides compounds of formula (I): | 2010-02-11 |
20100035927 | MEDICAMENT FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF ALZHEIMER-TYPE DEMENTIA - A medicament for prophylactic and/or therapeutic treatment of Alzheimer-type dementia, which comprises donepezil hydrochloride and valproic acid or a salt thereof in combination. | 2010-02-11 |
20100035928 | Method Of Treating Attention Deficit Disorders With D-Threo Methylphenidate - Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof. | 2010-02-11 |
20100035929 | UNNATURAL DISPYRIN ANALOGUES, PREPARATION AND USES THEREOF - Disclosed are dispyrin analogue compounds useful as H3 receptor activity modulators, methods of making same, pharmaceutical compositions comprising same, and methods of treating neurological and psychiatric disorders associated with histamine H3 receptor activity using same. In one aspect, the disclosed analogues can have a structure represented by a formula: | 2010-02-11 |
20100035930 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa - The invention relates to compounds of the formula I | 2010-02-11 |
20100035931 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS - The present invention is directed to tripyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2010-02-11 |
20100035932 | NOVEL FORMYL PEPTIDE RECEPTOR LIKE 1 AGONISTS THAT INDUCE MACROPHAGE TUMOR NECROSIS FACTOR ALPHA AND COMPUTATIONAL STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS OF THEREOF - The present invention provides compounds of structural formula (I), which are agonists of formyl peptide receptor (FPR), particularly formyl peptide receptor like 1 (FPRL1). The present invention also provides the therapeutic use of the compounds of formula (I). | 2010-02-11 |
20100035933 | Kits, Recloseable Containers, Blanks And Methods Of Treatment - Kits include a recloseable container and an inner container housed within the recloseable container. The recloseable container can include a front wall and a front flap operable to transition between an open position and a closed position, wherein the front flap releasably engages the front wall when in the closed position. Methods of treatment which utilize the kits are also disclosed. Blanks for the recloseable container are also disclosed. | 2010-02-11 |
20100035934 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel pyridinyl-pyrazole derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels. | 2010-02-11 |
20100035935 | ANTHRANILAMIDE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PESTICIDES CONTAINING THEM - Anthranilamide compounds, a process for their production, and pesticides containing these compounds as active ingredients. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way. | 2010-02-11 |
20100035936 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS - The present invention relates to heterocyclyl-substituted-tetrahydro-naphthalen compounds of general formula (I), methods for their preparation, and compositions comprising these compounds as well as their use for the treatment or prophylaxis of various disorders in humans or animals. | 2010-02-11 |
20100035937 | SOLUBILIZED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS - A process for producing a solubilized non-steroidal anti-inflammatory drug (NSAID) the process comprising the steps of: providing a mixture comprising solid NSAID and a first base which is selected from the group of bases which have a pH of at least 11 as 0.1 molar aqueous solution or dispersion, and reacting the NSAID and the first base in essentially dry state, solubilized NSAID obtainable by this process and pharmaceutical compositions comprising the same. | 2010-02-11 |
20100035938 | Cooling Compounds - A method of providing a cooling effect to a product includes the incorporation into the product of at least one compound of the formula I | 2010-02-11 |
20100035939 | PENETRATING CARRIER, ANTI-FUNGAL COMPOSITION USING THE SAME AND METHOD FOR TREATMENT OF DERMATOPHYTES - An antifungal liquid composition for topical administration is provided that contains turpentine and at least one of peppermint oil, mineral oil, and essential oil alcohols, and one or more antifungal medications selected from ciclopirox olamine, terbinafine, tolnaftate, microconazole, itraconazole, ketoconazole, econazole, and fluconazole, and optionally one or more antifungal essential oils, and its use in the topical treatment of fungal infection, particularly of the nail. | 2010-02-11 |
20100035940 | Cyclin Dependent Kinase Inhibitors - The invention relates to cyclin dependent kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer. | 2010-02-11 |
20100035941 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION - Methods for increasing blood flow and/or regenerating tissue using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z′) wherein Z is a cyclic polyamine containing 9-32 ring members of which 2-8 are nitrogen atoms, said nitrogen atoms separated from each other by at least 2 carbon atoms, and wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system; or Z is of the formula (I) wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1-20 atoms; Z′ may be embodied in a form as defined by Z above, or alternatively may be of the formula —N(R)—(CR | 2010-02-11 |
20100035942 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors - Compounds of the formula | 2010-02-11 |
20100035943 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors - Compounds formula (IA) or (IB), wherein W represents HO(C═O)—, HONH(C═O)— or H(C═O)N(OH)—; X represents —O— or —S—; and R | 2010-02-11 |
20100035944 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS - The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating G protein-coupled receptor 20 (GPR20), and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated GPR20. | 2010-02-11 |
20100035945 | SMALL MOLECULE INHIBITORS OF BACTERIAL DAM DNA METHYLTRANSFERASES - Disclosed are compounds, crystal structures, data representations, methods of using, and methods of identifying compounds in relation to DNA methylation and inhibition of methylation. In embodiments, DNA methylation is by DNA-adenine methyltransferases (Dam). In an embodiment, compounds are used to treat a host suspected of infection by a pathogenic organism. In an embodiment, virulence of a pathogenic bacterium is modified by treatment with an agent capable of inhibiting a bacterial Dam enzyme. In an embodiment, compounds and methods are disclosed regarding Dam inhibitors. | 2010-02-11 |
20100035946 | INDOLINE ANTI-CANCER AGENTS - Indoline compounds having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided. | 2010-02-11 |
20100035947 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES - A method for manufacturing neuraminic acid derivatives is provided, also synthetic intermediates of the neuraminic acid derivatives and methods for their manufacture, and neuraminic acid derivatives having high purity. | 2010-02-11 |
20100035948 | Furanone compounds and lactam analogues thereof - The present invention provides a compound of formula I and a compound of formula II, methods of use and formulations thereof. | 2010-02-11 |
20100035949 | MICROEMULSION DOSAGE FORMS OF VALSARTAN AND METHODS OF MAKING THE SAME - A drug delivery system, e.g., microemulsion preconcentrate, that spontaneously forms a microemulsion when brought in contact with an aqueous medium. The drug delivery system contains valsartan, a hydrophilic component, a lipophilic component and a surfactant. A particularly useful hydrophilic component in the system is a polymer that is solid at room temperature, e.g., solid PEG. | 2010-02-11 |
20100035950 | Microbiocidal Treatment Of Edible Fruits And Vegetables - Methods of controlling bacterial, yeast, and/or mold contamination of edible fruits or vegetables comprise applying thereto an aqueous microbiocidal composition stabilized against ultraviolet light-induced degradation formed from water and (A) at least one component selected from (I) a solid-state microbiocidal compound having at least one bromine atom per molecule; (II) an aqueous solution/slurry of a compound of (I); (III) a concentrated aqueous composition having an active bromine content of at least 50,000 ppm derived from water and (i) BrCl or BrCl and Br | 2010-02-11 |
20100035951 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS - This invention relates to 2-amino benzimidazole derivatives of Formula 1a or 1b: | 2010-02-11 |
20100035952 | Radiosensitizer Formulations and Methods for Use - The present invention provides radiosensitizer compositions, in controlled-release formulations or other acceptable formulations, particularly nitrohistidine radiosensitizer compositions, which may be administered by any suitable means including oral, intravenous, arterial infusion, intraperitoneal, intramuscular, subcutaneous, surgical, and topical. Optionally, radiosensitizer compositions may be formulated with other agents, including chemotherapy agents and agents that provide a synergistic radiosensitizing effect. Methods of potentiating radiotherapy cancer treatment of cancers in humans, particularly of astrocytomas, are also presented, wherein a radiosensitizer composition is administered and radiotherapy is directed to the site of the tumor. Chemotherapy regimens may also be used as adjuvant therapy. | 2010-02-11 |
20100035953 | Pyrazole Phenyl Derivatives - The invention relates to compounds of the formula I: | 2010-02-11 |
20100035954 | ACID ADDITION SALTS OF MUSCARINIC RECEPTOR ANTAGONISTS - Provided herein are acid addition salts of muscarinic receptor antagonists. Such acid addition salts are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Also provided herein are processes for the preparation of acid addition salts, pharmaceutical compositions thereof, and methods of treating diseases mediated through muscarinic receptors. | 2010-02-11 |
20100035955 | Stabilised Composition Comprising ACE Inhibitors - A pharmaceutical composition comprising a) an ACE inhibitor prone to degradation or a pharmaceutically acceptable acid addition salt thereof; b) a stabilizing amount of an alkaline stabilizing agent; and c) pharmaceutically acceptable excipients wherein the composition further includes moisture controlling means. | 2010-02-11 |
20100035956 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis. | 2010-02-11 |
20100035957 | Methods for the Use of Inhibitors of Cytosolic Phospholipase A2 - This invention provides methods for the use of substituted indole compounds of the general formula: | 2010-02-11 |
20100035958 | Novel Compounds And Compositions Thereof - The invention relates to novel compounds containing a carboxylic acid head group. The invention further provides compositions containing the novel compounds, a particulate solid and an organic medium or water. | 2010-02-11 |
20100035959 | Novel sphingosine kinase type 1 inhibitors, compositions and processes for using same - Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting survival signaling in cancer cells, and reducing symptoms of multiple sclerosis. | 2010-02-11 |
20100035960 | BIOSYNTHETIC PATHWAY AND GENES REQUIRED FOR TROPODITHIETIC ACID BIOSYNTHESIS IN SILICIBACTER TM1040 - Production and use of a sulfur-containing compound, tropodithietic acid (TDA), from the | 2010-02-11 |
20100035961 | Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof - This invention relates to Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof. | 2010-02-11 |
20100035962 | NOVEL 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH CYCLOHEXYL GROUPS, METHOD FOR PRODUCING THE SAME, DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF - This Invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof. | 2010-02-11 |
20100035963 | Oligoribonucleotides and Methods of use Thereof for Treatment of Cardiovascular Disease - The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of one or more cardiovascular-related gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a cardiovascular disorder or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. | 2010-02-11 |
20100035964 | ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION - Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided. | 2010-02-11 |
20100035965 | SIRNA INHIBITION OF P13K P85, PA110, AND AKT2 AND METHODS OF USE - The present invention provides polynucleotides, compositions including polynucleotides, and the uses thereof for treating cancer in a subject. The polynucleotides silence the expression of coding regions that encode polypeptides such as p85α, p110α, and Akt2. The cancers treatable using the methods described herein include colorectal cancer, breast cancer, lung cancer, and metastases thereof. | 2010-02-11 |
20100035966 | METHODS AND COMPOSITIONS FOR REGULATING CELL CYCLE PROGRESSION - In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5′ end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5″end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8. In some embodiments, the method comprises introducing at least one iRNA that inhibits the expression of at least one miR-16 responsive gene selected from TABLE 5 into the mammalian cell. | 2010-02-11 |
20100035967 | MODULATION OF TOLL-LIKE RECEPTOR 9 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES - Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR9. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR9. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR9 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR9 expression and for prevention or treatment of diseases wherein modulation of TLR9 expression would be beneficial are provided. | 2010-02-11 |
20100035968 | MEDIATED CELLULAR DELIVERY OF LNA OLIGONUCLEOTIDES - The present invention relates to novel modified oligomeric compounds and to methods of making and using such compounds. The invention further relates to methods of enhancing the cellular uptake of oligomeric compounds comprising conjugating a metal chelator to those. | 2010-02-11 |
20100035969 | RNAi INHIBITION OF CTGF FOR TREATMENT OF OCULAR DISORDERS - RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention. | 2010-02-11 |
20100035970 | Methylation Markers for Diagnosis and Treatment of Cancers - Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments. | 2010-02-11 |
20100035971 | Methods and Means Related to Diseases - The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products. The present invention further relates to a novel test kit, the kit comprising the necessary means for detecting one or more genes, gene fragments or gene products. The present invention also relates to a use of one or more genes, gene fragments or gene products for determination, diagnosis or follow-up of CTCL or CTCL subtype and for detection of the response to CTCL therapy. The present invention also relates to a use of one or more target molecules for CTCL therapy or for the preparation of a medicament for treating CTCL. | 2010-02-11 |
20100035972 | Oligonucleotide and use thereof - An oligonucleotide with a nucleotide sequence of 5′-cctcctcctcctcctcctcctcct-3′ (SEQ ID NO: 1) inhibits proliferation of human PBMC activated by TLR9 agonist and interferon production from human PBMC induced by TLR9 agonist, HSV-1, flu virus and serum from SLE patients, and rescues the mice from cytokine-mediated lethal shock. This oligonucleotide can be used as a remedy for the treatment of systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes and other immune-mediated disorders. | 2010-02-11 |
20100035973 | DISRUPTION OF PROGRAMMED DEATH 1 (PD-1) LIGAND TO ADJUVANT ADENO-ASSOCIATED VIRUS VECTOR VACCINES - The invention provides for methods of modulating an immune response against a therapeutic polypeptide or an antigenic polypeptide delivered via rAAV comprising administering a modulator of programmed death-1 (PD-1) signaling. | 2010-02-11 |
20100035974 | COMPOSITIONS COMPRISING A SIRNA AND LIPIDIC 4,5-DISUBSTITUTED 2-DEOXYSTREPTAMINE RING AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF - The present invention relates to a composition comprising a siRNA and a transfecting compound consisting of an aminoglycoside of the class of 4,5-disubstituted 2-deoxystreptamine ring linked via a spacer molecule to a lipid moiety of formula —(R1)R2 wherein R1 and R2 represent, independently of one another, a hydrogen atom or a fatty aliphatic chain or R1 or R2 is absent, with the proviso that at least one of R1 and R2 represents a fatty aliphatic chain; or —OR3 or —NR3 wherein R3 represents a steroidal derivative. The invention also concerns in vitro and in vivo applications of these compositions. | 2010-02-11 |
20100035975 | METHODS OF PREVENTING AND TREATING RESPIRATORY VIRAL INFECTION USING IMMUNOMODULATORY POLYNUCLEOTIDE SEQUENCES - The invention provides methods of preventing and/or treating infection by a respiratory virus such as respiratory syncytial virus (RSV), particularly reducing infection and/or one or more symptoms of respiratory virus infection. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual which is at risk of being exposed to a respiratory virus, has been exposed to a respiratory virus or is infected with a respiratory virus. The ISS is administered without any antigens of the respiratory virus. Administration of the ISS results in reduced incidence and/or severity of one or more symptoms of respiratory virus infection. | 2010-02-11 |
20100035976 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog - A method of treating a tumor or a viral disease by administering to a human the following 2′,5′-oligoadenylate analog: | 2010-02-11 |
20100035977 | TWO-COMPONENT TAXANE CONTAINING PHARMACEUTICAL COMPOSITION - A stabilized, injectable pharmaceutical composition for human administration comprises (a) an antineoplastic compound, (b) a solubilizing/dispersing agent, and (c) a stabilizing amount of an anti-oxidant. | 2010-02-11 |
20100035978 | COMBINATION OF CANNABINOIDS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN - The present invention relates to the use of a combination of cannabinoids in the treatment of neuropathic pain, in particular peripheral neuropathic pain. A combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may be used, wherein the ratio of CBD:THC by weight is between 10:1 and 1:10. | 2010-02-11 |
20100035979 | Compositions and Methods of Sensitizing Methicillin Resistant Staphylococcus Aureus to Oxacillin - Contemplated methods and compositions further increase susceptibility of sensitized MRSA against various antibiotic drugs. Most preferably, the MRSA is already sensitized with a galloylated catechin (e.g., ECG), and further sensitization is achieved by exposure to a non-galloylated catechin (e.g., EC), and most preferably the corresponding non-galloylated catechin. | 2010-02-11 |
20100035980 | ANTIPARASITIC AGENTS - The present invention relates to compounds of the formula (I) | 2010-02-11 |
20100035981 | PARTICULATE AQUEOUS SYSTEM FOR THE PREPARATION OF A FORMULATION FOR THE TREATMENT OF ADIPOSE DISEASES - Aqueous particulate system comprising at least one water dispersible biopolymer, at least one surfactant, and water for the preparation of a formulation for the treatment of adipose diseases and/or conditions with improved bioavailability and good retardation of the release of active substances. | 2010-02-11 |
20100035982 | OXALIPLATIN FORMULATIONS - The present invention provides a pharmaceutical liquid formulation of oxaliplatin for parenteral administration, said formulation having (i) oxaliplatin, (ii) water; and (iii) an additive selected from the group of tartaric acid, a salt of tartaric acid, a pharmaceutically acceptable derivative of tartaric acid and mixtures thereof. | 2010-02-11 |
20100035983 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF - The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection. | 2010-02-11 |
20100035984 | Use of an antibacterial compound which is derived from alliaceae, as a natural additive in animal feed - The invention relates to the use of an antibacterial compound, which is derived from alliaceae, as a natural additive in animal feed, intended as an antimicrobial agent in animal feed, and as an alternative, due to its antibacterial nature, to the use of antibiotics as growth promoters, proposing the use of the compound separately (purity greater than 95%), and encapsulated or supported on different inert materials or food coatings, and in that said compound preferably consists of propyl propylthiosulfinate and, in an alternative variant, of propyl propylthiosulfonate. | 2010-02-11 |
20100035985 | Ester Compound and Use Thereof - An ester compound represented by the formula (1): | 2010-02-11 |
20100035986 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION - A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C | 2010-02-11 |
20100035987 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES - A pleuromutilin derivative compound of general formula (I) | 2010-02-11 |
20100035988 | Methods for activating PPAR gamma-type receptors - Novel biaromatic compounds having the following structural formula (I): | 2010-02-11 |
20100035989 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS - The invention relates to methods of treating mucositis comprising administering a compound of formula A, compound of any one of formulae 1 to 46, lipoxin compound, or oxylipin compound. | 2010-02-11 |
20100035990 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) - Omega-3 lipid compounds of the general formula (I): | 2010-02-11 |
20100035991 | AMIDE BASE SALTS OF SAHA AND POLYMORPHIS THEREOF - The present invention provides amine base salts of SAHA, polymorphs and pharmaceutical compositions thereof. The invention provides a method of treating cancer by administering the pharmaceutical composition. The invention also provides a crystalline composition comprising the amine base and SAHA. The invention also provides methods of obtaining the amine base salt and crystalline composition. | 2010-02-11 |
20100035992 | Methods and Compositions for Treating Inflammation and Inflammation-Related Pathologies - Methods and compositions are provided for the treatment of inflammation and disorders, diseases, and adverse conditions, i.e., pathologies, caused by or otherwise associated with inflammatory processes. A metal ion sequestering agent that directly or indirectly exerts an anti-inflammatory effect is administered to a subject in combination with a sequestration inactivating moiety that facilitates transport of the metal ion sequestering agent through biological membranes. The sequestration inactivating moiety also inactivates the metal ion sequestering agent until association between the two components is cleaved in vivo to release the active sequestering agent. Compositions containing a metal ion sequestering agent and a sequestration inactivating moiety are also provided; the compositions optionally contain an added anti-inflammatory agent. | 2010-02-11 |
20100035993 | METHODS AND COMPOSITIONS COMPRISING 2-[(3-CHLOROPHENYL) AMINO] PHENYLACETIC ACID FOR HYPERPERMEABILITY AND NEOVASCULARIZATION DISORDERS OF THE RETINA - Method of preventing or arresting the progression of hyperpermeability and neovascularization of the retina by administering to a patient at risk for retinal microvascular disease a composition comprising a compound or pharmaceutically acceptable salt thereof that lowers the ocular ratio of VEGF to PEDF. | 2010-02-11 |
20100035994 | NOVEL HYDRATE FORM OF O-DESMETHYL VENLAFAXINE SUCCINATE - The present invention relates to a novel hydrate form of O-desmethyl venlafaxine succinate. The present invention further relates to processes for the preparation of the novel hydrate form, pharmaceutical compositions comprising it, second medical uses of the novel hydrate form, and methods using it for treating diseases such as generalised anxiety disorder, anxiety, depressive disorder, depression and panic disorder. | 2010-02-11 |
20100035995 | Compositions comprising Cyclohexylamines and Aminoadamantanes - The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container. | 2010-02-11 |
20100035996 | GLUCOSE METABOLISM STIMULATING AGENT - A compound of the formula I: | 2010-02-11 |
20100035997 | KIT FOR APPLYING A POLYMERIZABLE ADHESIVE COMPOSITION TO TISSUES - The invention relates to a kit for the topical and/or internal application of a polymerisable adhesive composition to tissues, enabling improved control of the polymerisation speed on the surface of the tissue, in addition to the effective disinfection of the wound. The kit consists of at least one receptacle and contains a polymerisable adhesive composition based on cyanacrylate, in addition to a disinfectant composition. | 2010-02-11 |
20100035998 | COMBINATION S-NITROSOTHIOL PHARMACEUTICAL PRODUCTS FOR RESTORING NORMAL BREATHING RHYTHMS - The present invention is directed to a method of treating a lack of normal breathing control including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions. In an aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a combination of two or more compounds, at least one of which treats lack of normal breathing. In one aspect, a compound is an S-nitrosylating agent. | 2010-02-11 |
20100035999 | Additives and products includings oligoesters - The present invention relates to oligoesters and their use for the creation of additives. Oligoester containing additives and/or oligoesters themselves may be used for formulating pharmaceutical preparations, cosmetics or personal care products such as shampoos and conditioners. These oligoesters are particularly useful for the creation of multi-purpose additives that can impart conditioning, long substantivity and/or UV protection. Individual oligoesters and oligoester mixtures are described. | 2010-02-11 |
20100036000 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2010-02-11 |
20100036001 | HEPAROSAN POLYMERS AND METHODS OF MAKING AND USING SAME FOR THE ENHANCEMENT OF THERAPEUTICS - The present invention includes compositions, methods, and systems for the development and use of heparosan, a natural polymer related to heparin, as a new therapeutic modifying agent or vehicle which can modulate drug cargo pharmacokinetics and behavior within a mammalian patient. | 2010-02-11 |
20100036002 | PHARMACEUTICAL COMPOSITION COMPRISING POROUS DRY MATRIX - The invention provides a porous dry matrix preparation comprising at least a polymeric thickener and an excipient ingredient, wherein (1) the content of the polymeric thickener is down to 0.5 w/w % and up to 14 w/w %, (2) the content of the excipient ingredient is down to 30 w/w % and up to 80 w/w %, (3) the void ratio is not less than 20%, and (4) the water activity is not more than 0.55, or water content is not more than 10 w/w %. | 2010-02-11 |
20100036003 | HYDROFORMYLATION PROCESS - A hydroformylation process comprising reacting, in a reactor system comprising one or more feed streams, a reaction environment and an output stream, a feedstock composition comprising a compound having at least one olefinic carbon- to- carbon bond with hydrogen and carbon monoxide in the presence of an organophosphine modified cobalt hydroformylation catalyst, wherein the hydroformylation process is carried out in the reaction environment, which comprises at least two reaction zones, wherein the at least two reaction zones comprise an earlier reaction zone and a later reaction zone, wherein the temperature of the later reaction zone is at a temperature which is at least 2° C. greater than the temperature in the earlier reaction zone, and the temperature of the later reaction zone is in the range of from 140° C. to 220° C., and the temperature of the earlier reaction zone is at least 130° C., and wherein water is added into the reactor system. | 2010-02-11 |
20100036004 | WATER-ABSORBING POLYMER STRUCTURE WITH A HIGH AMMONIA-BINDING CAPACITY - The present invention relates to a process for the production of a water-absorbing polymer structure, comprising the process steps:
| 2010-02-11 |
20100036005 | FOAMED RUBBER MEMBER - An object of the present invention is to provide a foamed rubber member which has low hardness and excellent durability. The foamed rubber member of the invention, produced through an impregnation treatment of a foamed elastic body with a treatment liquid containing an isocyanate compound and an organic solvent, the foamed elastic body being produced by foaming a base rubber, exhibits a compression set smaller than that of the foamed elastic body before undergoing the impregnation treatment, and exhibits a percent increase in stress, with respect to the stress of the foamed elastic body before undergoing the impregnation treatment, of 50% or less. | 2010-02-11 |
20100036006 | RUBBER COMPOSITION AND PNEUMATIC TIRE USING THE SAME - The present invention provides a rubber composition which has closed cells and comprises (A) at least one rubber component selected from natural rubber and diene-based synthetic rubbers, (B) silica in an amount of 10 to 150 parts by mass based on 100 parts by mass of the rubber component, (C) an organic fiber in an amount of 0.02 to 20 parts by mass based on 100 parts by mass of the rubber component and (D) a silane coupling agent represented by following general formula (I): | 2010-02-11 |
20100036007 | FOAM OF POLYMERS - The disclosure pertains to foam of polymers, which can be made by a method for making a polymer foam comprising vacuum or gas-filled compartments by making a solution of 1 to 20% by weight of a polymer in a solvent; adding particles to the a polymer solution; solidifying the polymer wherein the particles are contained by heating, cooling, ageing, or coagulating to obtain a polymer foam or matrix comprising the particles, and obtaining from the polymer matrix the polymer foam containing the compartments; and optionally washing, drying, and/or heating the polymer foam. | 2010-02-11 |
20100036008 | HIGHLY ELASTIC FLEXIBLE POLYURETHANE FOAMS - The present invention relates to a highly elastic flexible polyurethane foam obtainable by mixing a) polyisocyanate with b) at least one relatively high molecular weight compound having at least two reactive hydrogen atoms, c) hyperbranched polyester c1) of the A | 2010-02-11 |
20100036009 | PROCESS FOR PRODUCING MICROPOROUS POLYMERIC OBJECT, AND MICROPOROUS POLYMERIC OBJECT AND SEPARATION MEMBRANE - A process for producing a microporous polymeric object to improve the degree of freedom for its various properties, compared to conventional processes, includes: mixing a block copolymer made of three or more kinds of segments with a polymer, wherein one or more of the segments are made of monomer units having a first functional group forming ionic and/or hydrogen bond, the segments constitute a co-continuous structure having mutually-independent and continuous regions due to a phase separation based on incompatibility between the segments, and the polymer has, at other than polymer chain terminals, a second functional group forming such bond with the first functional group, thereby allowing the segments to associate with the polymer at many points; forming a co-continuous structure including a region composed of the polymer and the segments due to the phase separation; and removing the polymer from the region by weakening the bond between the functional groups. | 2010-02-11 |
20100036010 | Amine-initiated polyols and rigid polyurethane foam made therefrom - Polyether polyols are initiated with aminocyclohexanealkylamines such as isophoronediamine and 1,8-diaminop-menthane. The polyols are useful in making rigid polyurethane foams, especially foams for pour-in-place applications, where they give a good combination of low k-factor and short demold times. | 2010-02-11 |
20100036011 | NEW TYPES OF COMPATIBILISING AGENTS FOR IMPROVING THE STORAGE OF POLYOL MIXTURES - The invention relates to polyethers containing urethane or urea groups as compatibilizing agents, their preparation and use, obtained by the reaction of
| 2010-02-11 |